Page last updated: 2024-11-04

vorinostat and Diffuse Large B-Cell Lymphoma

vorinostat has been researched along with Diffuse Large B-Cell Lymphoma in 17 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Research Excerpts

ExcerptRelevanceReference
"A panel of rituximab-chemotherapy-sensitive (RSCL) and rituximab-chemotherapy-resistant cell lines (RRCL) and primary tumor cells isolated from relapsed/refractory B cell lymphoma patients were exposed to escalating doses of vorinostat."7.83Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents. ( Czuczman, MS; Gu, JJ; Guo, Y; Hernandez-Ilizaliturri, FJ; Mavis, C; Xue, K; Zhang, Q, 2016)
" S0806 was a single arm phase I/II trial of vorinostat given at 400 mg po daily on days 1-9 (subsequently amended to days 1-5 due to toxicity), combined with R-CHOP given on day 3 of a 21-day cycle for 8 cycles, with primary phase II endpoint of 2-year progression free survival (PFS)."6.87A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. ( Bane, CL; Barr, PM; Fisher, RI; Friedberg, JW; LeBlanc, M; Li, H; Persky, DO; Popplewell, LL; Rimsza, LM; Smith, SM; Von Gehr, A, 2018)
"Vorinostat (400 mg) was administered orally on days 1 to 5 and 8 to 12 before bortezomib (1."6.87A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma. ( Badros, AZ; Baz, R; Bose, P; Coppola, D; Flowers, C; Grant, S; Holkova, B; Kimball, A; Kmieciak, M; Lin, HY; Morgan, D; Parekh, S; Perkins, EB; Reich, RR; Richards, KL; Roberts, JD; Ruan, J; Sankala, H; Shafer, D; Shea, T; Shrader, E; Sokol, L; Strair, R; Sullivan, D; Tombes, MB; Yazbeck, V; Zhao, X, 2018)
"The standard treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in frail elderly patients has not been established."6.80Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation. ( Cella, D; Drullinsky, PR; Elstrom, R; Gerecitano, JF; Hamilton, AM; Hamlin, PA; Lia Palomba, M; Matasar, MJ; Noy, A; Straus, DJ; Wegner, B; Wortman, K; Zelenetz, AD, 2015)
"Cladribine is a purine nucleoside analog used to treat B-cell chronic lymphocytic leukemia and hairy cell leukemia, also functions as an inhibitor of DNA synthesis to block the repair of the damaged DNA."5.56Cladribine Induces ATF4 Mediated Apoptosis and Synergizes with SAHA in Diffuse Large B-Cell Lymphoma Cells. ( Gao, X; Jiao, J; Li, Z; Liu, M; Qin, Y; Sang, W; Song, X; Sun, C; Sun, X; Tian, Y; Xu, K; Xu, L; Yan, D; Yang, P; Zeng, L; Zhu, F, 2020)
"A panel of rituximab-chemotherapy-sensitive (RSCL) and rituximab-chemotherapy-resistant cell lines (RRCL) and primary tumor cells isolated from relapsed/refractory B cell lymphoma patients were exposed to escalating doses of vorinostat."3.83Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents. ( Czuczman, MS; Gu, JJ; Guo, Y; Hernandez-Ilizaliturri, FJ; Mavis, C; Xue, K; Zhang, Q, 2016)
"Interactions between histone deacetylase inhibitors (HDACIs) and the novel proteasome inhibitor carfilzomib (CFZ) were investigated in GC- and activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL) cells."3.76The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. ( Dasmahapatra, G; Dent, P; Fisher, RI; Friedberg, J; Grant, S; Kramer, L; Lembersky, D, 2010)
" S0806 was a single arm phase I/II trial of vorinostat given at 400 mg po daily on days 1-9 (subsequently amended to days 1-5 due to toxicity), combined with R-CHOP given on day 3 of a 21-day cycle for 8 cycles, with primary phase II endpoint of 2-year progression free survival (PFS)."2.87A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. ( Bane, CL; Barr, PM; Fisher, RI; Friedberg, JW; LeBlanc, M; Li, H; Persky, DO; Popplewell, LL; Rimsza, LM; Smith, SM; Von Gehr, A, 2018)
"Vorinostat (400 mg) was administered orally on days 1 to 5 and 8 to 12 before bortezomib (1."2.87A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma. ( Badros, AZ; Baz, R; Bose, P; Coppola, D; Flowers, C; Grant, S; Holkova, B; Kimball, A; Kmieciak, M; Lin, HY; Morgan, D; Parekh, S; Perkins, EB; Reich, RR; Richards, KL; Roberts, JD; Ruan, J; Sankala, H; Shafer, D; Shea, T; Shrader, E; Sokol, L; Strair, R; Sullivan, D; Tombes, MB; Yazbeck, V; Zhao, X, 2018)
"The standard treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in frail elderly patients has not been established."2.80Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation. ( Cella, D; Drullinsky, PR; Elstrom, R; Gerecitano, JF; Hamilton, AM; Hamlin, PA; Lia Palomba, M; Matasar, MJ; Noy, A; Straus, DJ; Wegner, B; Wortman, K; Zelenetz, AD, 2015)
"Vorinostat was given at 200 mg/day to 1000 mg/day (days -8 to -3)."2.80Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. ( Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Bashir, Q; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hagemeister, F; Hosing, C; Jones, RB; Liu, Y; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shah, N; Shpall, EJ; Thall, PF; Valdez, BC, 2015)
"Vorinostat was well tolerated at 300 mg b."2.73Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. ( Cheson, BD; Coiffier, B; Crump, M; Frankel, SR; Jacobsen, ED; Randolph, SS; Ricker, JL; Sun, L; Xie, H, 2008)
"Cladribine is a purine nucleoside analog used to treat B-cell chronic lymphocytic leukemia and hairy cell leukemia, also functions as an inhibitor of DNA synthesis to block the repair of the damaged DNA."1.56Cladribine Induces ATF4 Mediated Apoptosis and Synergizes with SAHA in Diffuse Large B-Cell Lymphoma Cells. ( Gao, X; Jiao, J; Li, Z; Liu, M; Qin, Y; Sang, W; Song, X; Sun, C; Sun, X; Tian, Y; Xu, K; Xu, L; Yan, D; Yang, P; Zeng, L; Zhu, F, 2020)
" Here, we report in vivo data for OTX015 in combination with the histone deacetylase inhibitor vorinostat, the Bruton's tyrosine kinase inhibitor ibrutinib, the anti-CD20 monoclonal antibody rituximab, and the mTOR inhibitor everolimus in a diffuse large B cell lymphoma model."1.43Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma. ( Bernasconi, E; Bertoni, F; Cascione, L; Cvitkovic, E; Gaudio, E; Odore, E; Ponzoni, M; Rezai, K; Rinaldi, A; Riveiro, E; Stathis, A; Tarantelli, C; Zucca, E, 2016)

Research

Studies (17)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (11.76)29.6817
2010's11 (64.71)24.3611
2020's4 (23.53)2.80

Authors

AuthorsStudies
Zhang, K1
Huang, L1
Lai, F1
Lin, S1
Tian, H1
Wu, D1
Chen, X1
Xu, H1
Wang, X2
Hong, Y1
Meng, S1
Gong, W1
Ren, T1
Zhang, T1
Liu, X1
Li, L1
Qiu, L1
Qian, Z1
Zhou, S1
Zhao, M1
Zhai, Q1
Meng, B1
Ren, X1
Zhang, H1
Alkhaldi, H1
Reinhardt, A1
Barnett, M1
Kundu, S1
Hosing, C2
Ramdial, J1
Saini, N1
Srour, S1
Alousi, A2
Kebriaei, P1
Popat, U2
Qazilbash, M2
Champlin, R2
Shpall, EJ2
Gulbis, A2
Shigle, TL1
Dabaja, B2
Pinnix, C2
Ahmed, S2
Steiner, R1
Andersson, BS2
Nieto, Y2
Xu, L1
Jiao, J1
Sun, X1
Sang, W1
Gao, X1
Yang, P1
Yan, D1
Song, X1
Sun, C1
Liu, M1
Qin, Y1
Tian, Y1
Zhu, F1
Zeng, L1
Li, Z1
Xu, K1
Persky, DO1
Li, H1
Rimsza, LM1
Barr, PM1
Popplewell, LL1
Bane, CL1
Von Gehr, A1
LeBlanc, M1
Fisher, RI2
Smith, SM1
Friedberg, JW1
Yazbeck, V1
Shafer, D1
Perkins, EB1
Coppola, D1
Sokol, L1
Richards, KL1
Shea, T1
Ruan, J2
Parekh, S1
Strair, R1
Flowers, C1
Morgan, D1
Kmieciak, M1
Bose, P1
Kimball, A1
Badros, AZ1
Baz, R1
Lin, HY1
Zhao, X1
Reich, RR1
Tombes, MB1
Shrader, E1
Sankala, H1
Roberts, JD1
Sullivan, D1
Grant, S2
Holkova, B1
Straus, DJ1
Hamlin, PA1
Matasar, MJ1
Lia Palomba, M1
Drullinsky, PR1
Zelenetz, AD1
Gerecitano, JF1
Noy, A1
Hamilton, AM1
Elstrom, R3
Wegner, B1
Wortman, K1
Cella, D1
Valdez, BC1
Thall, PF1
Jones, RB1
Anderlini, P1
Shah, N1
Bashir, Q1
Liu, Y1
Oki, Y1
Hagemeister, F1
Fanale, M1
Fernández-Rodríguez, C1
Salar, A1
Navarro, A1
Gimeno, E1
Pairet, S1
Camacho, L1
Ferraro, M1
Serrano, S1
Besses, C1
Bellosillo, B1
Sanchez-Gonzalez, B1
Xue, K1
Gu, JJ1
Zhang, Q1
Mavis, C1
Hernandez-Ilizaliturri, FJ1
Czuczman, MS1
Guo, Y1
Dupéré-Richer, D1
Kinal, M1
Pettersson, F1
Emond, A1
Calvo-Vidal, MN1
Nichol, JN1
Guilbert, C1
Plourde, D1
Klein Oros, K1
Nielsen, TH1
Ezponda, T1
Licht, JD1
Johnson, NA1
Assouline, S1
Cerchietti, L2
Miller, WH1
Mann, KK1
Pera, B1
Tang, T1
Marullo, R1
Yang, SN1
Ahn, H1
Patel, J1
Furman, R1
Leonard, J1
Martin, P2
Gaudio, E1
Tarantelli, C1
Ponzoni, M1
Odore, E1
Rezai, K1
Bernasconi, E1
Cascione, L1
Rinaldi, A1
Stathis, A1
Riveiro, E1
Cvitkovic, E1
Zucca, E1
Bertoni, F1
Leonard, JP1
Barrientos, J1
Dasmahapatra, G1
Lembersky, D1
Kramer, L1
Friedberg, J1
Dent, P1
Smeltzer, JP1
Viswanatha, DS1
Habermann, TM1
Patnaik, MM1
Crump, M1
Coiffier, B1
Jacobsen, ED1
Sun, L1
Ricker, JL1
Xie, H1
Frankel, SR1
Randolph, SS1
Cheson, BD1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Vorinostat (SAHA) Combined With High-Dose Gemcitabine, Busulfan, and Melphalan With Autologous Hematopoietic Cell Support for Patients With Relapsed or Refractory Lymphoid Malignancies[NCT01421173]Phase 178 participants (Actual)Interventional2011-08-31Completed
A Phase II Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)[NCT00097929]Phase 218 participants (Actual)Interventional2005-05-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for vorinostat and Diffuse Large B-Cell Lymphoma

ArticleYear
Targeted treatment and new agents in diffuse large B-cell lymphoma.
    Seminars in hematology, 2008, Volume: 45, Issue:3 Suppl 2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bor

2008

Trials

6 trials available for vorinostat and Diffuse Large B-Cell Lymphoma

ArticleYear
A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806.
    American journal of hematology, 2018, Volume: 93, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cy

2018
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.
    Clinical lymphoma, myeloma & leukemia, 2018, Volume: 18, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Drug Res

2018
Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation.
    British journal of haematology, 2015, Volume: 168, Issue:5

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap

2015
Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:11

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Dr

2015
Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.
    Clinical epigenetics, 2016, Volume: 8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2016
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug

2008

Other Studies

10 other studies available for vorinostat and Diffuse Large B-Cell Lymphoma

ArticleYear
Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma.
    Bioorganic & medicinal chemistry letters, 2022, 09-01, Volume: 71

    Topics: Animals; Apoptosis; Cell Line, Tumor; Histone Deacetylase Inhibitors; Humans; Lymphoma, Large B-Cell

2022
A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma.
    Clinical immunology (Orlando, Fla.), 2022, Volume: 243

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha

2022
High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.
    Transplantation and cellular therapy, 2023, Volume: 29, Issue:11

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Huma

2023
Cladribine Induces ATF4 Mediated Apoptosis and Synergizes with SAHA in Diffuse Large B-Cell Lymphoma Cells.
    International journal of medical sciences, 2020, Volume: 17, Issue:10

    Topics: Activating Transcription Factor 4; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell

2020
Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells.
    Leukemia & lymphoma, 2016, Volume: 57, Issue:3

    Topics: Acetylation; Antineoplastic Agents; Apoptosis; Bendamustine Hydrochloride; Cell Line, Tumor; Cell Su

2016
Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Journal of cancer research and clinical oncology, 2016, Volume: 142, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Burkitt Lymphoma; Cell Growth Processes;

2016
Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors.
    Leukemia & lymphoma, 2017, Volume: 58, Issue:1

    Topics: Animals; Antineoplastic Agents; Boron Compounds; Bortezomib; Drug Resistance, Neoplasm; Gene Express

2017
Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
    Oncotarget, 2016, Sep-06, Volume: 7, Issue:36

    Topics: Acetanilides; Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Antineop

2016
The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.
    Blood, 2010, Jun-03, Volume: 115, Issue:22

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Chymotrypsin; DNA

2010
Secondary Epstein-Barr virus associated lymphoproliferative disorder developing in a patient with angioimmunoblastic T cell lymphoma on vorinostat.
    American journal of hematology, 2012, Volume: 87, Issue:9

    Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Epstein-Barr Virus Infections; Female; Humans; Hydro

2012